| pubmed-article:7564103 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7564103 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7564103 | lifeskim:mentions | umls-concept:C0227651 | lld:lifeskim |
| pubmed-article:7564103 | lifeskim:mentions | umls-concept:C0128897 | lld:lifeskim |
| pubmed-article:7564103 | lifeskim:mentions | umls-concept:C0024027 | lld:lifeskim |
| pubmed-article:7564103 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:7564103 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:7564103 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7564103 | pubmed:dateCreated | 1995-11-14 | lld:pubmed |
| pubmed-article:7564103 | pubmed:abstractText | Macrophages play a critical role in the progression of clinical and experimental glomerular injury. Serum-stimulated human fetal mesangial cells in culture produce a chemotactic factor that is monocyte-selective. This chemotactic factor is most likely monocyte chemoattractant protein-1 (MCP-1) as a monoclonal antibody directed against MCP-1, but not an irrelevant antibody, suppressed the mesangial cell-derived chemotactic activity. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase by lovastatin resulted in a reduction of the mesangial cell-derived chemotactic activity as well as MCP-1 mRNA expression. The inhibitory effects of lovastatin in the presence of exogenous cholesterol were reversed by mevalonate, suggesting a role for isoprenoid intermediates of the mevalonate pathway and/or isoprenylated proteins in mesangial cell MCP-1 regulation. These findings suggest an additional mechanism by which HMG-CoA reductase inhibition in vivo may reduce glomerular injury. | lld:pubmed |
| pubmed-article:7564103 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7564103 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7564103 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7564103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7564103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7564103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7564103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7564103 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7564103 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7564103 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:7564103 | pubmed:author | pubmed-author:KimYY | lld:pubmed |
| pubmed-article:7564103 | pubmed:author | pubmed-author:KimS YSY | lld:pubmed |
| pubmed-article:7564103 | pubmed:author | pubmed-author:KeaneW FWF | lld:pubmed |
| pubmed-article:7564103 | pubmed:author | pubmed-author:KasiskeB LBL | lld:pubmed |
| pubmed-article:7564103 | pubmed:author | pubmed-author:GuijarroCC | lld:pubmed |
| pubmed-article:7564103 | pubmed:author | pubmed-author:O'DonnellM... | lld:pubmed |
| pubmed-article:7564103 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7564103 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:7564103 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7564103 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7564103 | pubmed:pagination | 363-71 | lld:pubmed |
| pubmed-article:7564103 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:meshHeading | pubmed-meshheading:7564103-... | lld:pubmed |
| pubmed-article:7564103 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7564103 | pubmed:articleTitle | Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. | lld:pubmed |
| pubmed-article:7564103 | pubmed:affiliation | Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA. | lld:pubmed |
| pubmed-article:7564103 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7564103 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7564103 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7564103 | lld:pubmed |
